Cell health assessment is the foundation in cancer drug discovery. Potential cancer drug candidates need to show anti-cancer activity such as inhibition of proliferation and induction of apoptosis to ...

Although chimeric antigen receptor (CAR)-T therapy — where a patient’s T cells are engineered to fight cancer — works well against blood cancers in young people, that success drops dramatically for ...

This article is based on a poster originally authored by Yongyang Huang, Ning Guo, Mackenzie Pierce, Leo Chan, Bo Lin and Yi Yang, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...

The CellTiter-Glo® Luminescent Cell Viability Assay uses luminescence to accurately determine the number of viable cells in a culture. Sequentially process plates exhibiting a highly consistent ...

MADISON, Wis.--(BUSINESS WIRE)--Researchers working with bioluminescence now have a more accessible and cost-effective tool for their studies. The newly launched MyGlo™ Reagent Reader from Promega ...

Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.

From axolotls to zebrafish, stem cells possess remarkable regenerative abilities, enabling them to restore lost limbs and repair damaged organs. These extraordinary capabilities, however, are not ...

Adoptive cell therapies, also known as cellular immunotherapies, are a personalized treatment strategy that involves engineering patients’ immune cells to recognize and attack their own tumors. This ...